|
Friday, November 20, 2015
Print Current Session:
 |
|
|
Friday
SESSION 81:
MORE NEW DEVELOPMENTS IN CAROTID DISEASE, ONGOING TRIALS AND CONTROVERSIES
Moderators:Brajesh K. Lal, MD / Frank J. Veith, MD
|
|
| SESSION 81 SCHEDULE | |
| 1:00 PM - 1:05 PM | Predictors Of Stroke And Death After CAS: Post-Stent Ballooning Is Bad And Proper Use Of Beta Blockers Is Good: Data From The SVS VQI |
| Presenter(s):Mahmoud B. Malas, MD, MHS | |
| View Slides in PDF | |
| 1:06 PM - 1:11 PM | Guidelines For Management Of Carotid Stenosis Are Outdated, Inconsistent And Flawed: It Is Time For An Overhaul And Update |
| Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
| View Slides in PDF | |
| 1:12 PM - 1:17 PM | How Do The SVS Guidelines For Management Of Extracranial Carotid Disease Impact On Clinical Practice: Do They Need To Be Updated |
| Presenter(s):Enrico Ascher, MD | |
| View Slides in PDF | |
| 1:18 PM - 1:23 PM | What Are The Ongoing Carotid Trials (CREST-2, SPACE-2, ACST-2, ACT-1, ECST-2) Telling Us And Going To Tell Us |
| Presenter(s):Alison Halliday, MS, FRCS | |
| View Slides in PDF | |
| 1:24 PM - 1:29 PM | Status Of The SPACE-2 Trial: Although Patient Enrollment Has Been Stopped, What Useful Information Will It Provide |
| Presenter(s):Hans-Henning Eckstein, MD, PhD | |
| View Slides in PDF | |
| 1:30 PM - 1:35 PM | What Is Happening With CREST-2: When Will We Have Answers |
| Presenter(s):Thomas G. Brott, MD / Brajesh K. Lal, MD | |
| View Slides in PDF | |
| 1:36 PM - 1:41 PM | Why CREST-2 May Be A Bad Deal For CAS |
| Presenter(s):Mark H. Wholey, MD | |
| 1:42 PM - 1:47 PM | Double Filtration Embolic Brain Protection During CAS Improves Outcomes: A Novel PTA Balloon With An Integrated Filter Helps To Do This: The Paladin Balloon |
| Presenter(s):Ravish Sachar, MD | |
| View Slides in PDF | |
| Moderator(s): Thomas G. Brott, MD / Mark H. Wholey, MD | |
| 1:48 PM - 1:53 PM | DEBATE: Which Carotid Stenosis Patients Are Candidates For CAS In 2015: An Interventionist’s View |
| Presenter(s):Klaus D. Mathias, MD | |
| View Slides in PDF | |
| 1:54 PM - 1:59 PM | DEBATE: Which Carotid Stenosis Patients Are Appropriate Candidates For CAS In 2015: A Vascular Surgeon’s View |
| Presenter(s):Bruce A. Perler, MD, MBA | |
| View Slides in PDF | |
| 2:00 PM - 2:05 PM | What Lesion Characteristics Are Higher Risk For CAS Than CEA: How Should They Influence The Choice Of Treatment In Symptomatic And Asymptomatic Patients: Data From CREST |
| Presenter(s):Wesley S. Moore, MD | |
| View Slides in PDF | |
| 2:06 PM - 2:11 PM | DEBATE: Screening For Asymptomatic Carotid Stenosis (ACS) Is Justified In Some Patients: Which Ones And For What Reason |
| Presenter(s):Glenn Jacobowitz, MD | |
| View Slides in PDF | |
| 2:12 PM - 2:17 PM | DEBATE: Screening For ACS Is |
| Presenter(s):Erich Minar, MD | |
| View Slides in PDF | |
| 2:18 PM - 2:23 PM | CEA, CAS And Best Medical Treatment (BMRx) Alone: Which Treatment For Which Patient |
| Presenter(s):R. Clement Darling III, MD | |
| View Slides in PDF | |
| 2:24 PM - 2:29 PM | Early Intervention After Symptom Onset Is Safe With CEA But Not With CAS |
| Presenter(s):Hans-Henning Eckstein, MD, PhD | |
| View Slides in PDF | |
| 2:30 PM - 2:36 PM | Panel Discussion |
| END OF SESSION 81 | |
| previous | next |